Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients

详细信息    查看全文

• 作者：Madiha Akram (1)
  Muhammad Idrees (1)
  Shamail Zafar (2)
  Abrar Hussain (1)
  Sadia Butt (1)
  Samia Afzal (1)
  Irshad-ur Rehman (1)
  Ali Liaqat (1)
  Sana Saleem (1)
  Muhammad Ali (1)
  Azeem Butt (1)
  
• 刊名：Virology Journal
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：8
• 期：1
• 全文大小：493KB
• 参考文献：1. Koziel MJ, Peters MG: Viral hepatitis in HIV infection. / N Engl J Med 2007, 356:1445-454. CrossRef
  2. Kao JH, Chen DS: Transmission of hepatitis C virus in Asia: past and present perspectives. / J Gastroenterol Hepatol 2000,15(Suppl):E91-6. CrossRef
  3. Hoofnagle JH, di Bisceglie AM: The treatment of chronic viral hepatitis. / N Engl J Med 1997, 336:347-56. CrossRef
  4. McHutchison JG, Patel K: Future therapy of hepatitis C. / Hepatology 2002, 36:S245-52. CrossRef
  5. Fried MW, Hadziyannis SJ: Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. / Semin Liver Dis 2004,24(Suppl 2):47-4. CrossRef
  6. Wohnsland A, Hofmann WP, Sarrazin C: Viral determinants of resistance to treatment in patients with hepatitis C. / Clin Microbiol Rev 2007, 20:23-8. CrossRef
  7. Idrees M, Riazuddin S: A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. / BMC Gastroenterol 2009, 9:5. CrossRef
  8. Poordad F, Reddy KR, Martin P: Rapid virologic response: a new milestone in the management of chronic hepatitis C. / Clin Infect Dis 2008, 46:78-4. CrossRef
  9. Yu ML, Chuang WL: Treatment of chronic hepatitis C in Asia: when East meets West. / J Gastroenterol Hepatol 2009, 24:336-45. CrossRef
  10. Lee SS, Ferenci P: Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. / Antivir Ther 2008,13(Suppl 1):9-6.
  11. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. / Hepatology 2003, 38:645-52. CrossRef
  12. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. / Hepatology 1995, 22:1050-056. CrossRef
  13. Jafri W, Subhan A: Hepatitis C in Pakistan: magnitude, genotype, disease characteristics and therapeutic response. / Trop Gastroenterol 2008, 29:194-01.
  14. Lauer GM, Walker BD: Hepatitis C virus infection. / N Engl J Med 2001, 345:41-2. CrossRef
  15. Idrees M: Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. / J Virol Methods 2008, 150:50-6. CrossRef
  16. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). / Lancet 1998, 352:1426-432. CrossRef
  17. Soriano V, Peters MG, Zeuzem S: New therapies for hepatitis C virus infection. / Clin Infect Dis 2009, 48:313-20. CrossRef
  18. Hadziyannis SJ, Papatheodoridis GV: Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. / Expert Opin Pharmacother 2003, 4:541-51.
  19. Zuberi BF, Zuberi FF, Memon SA, Qureshi MH, Ali SZ, Afsar S: Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population. / World J Gastroenterol 2008, 14:2218-221. CrossRef
  20. Shin SR, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW: Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. / J Gastroenterol Hepatol 2010, 25:957-63. CrossRef
  21. Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z: Hepatitis C Treatment: current and future perspectives. / Virol J 2010, 7:296. CrossRef
  
• 作者单位：Madiha Akram (1)
  Muhammad Idrees (1)
  Shamail Zafar (2)
  Abrar Hussain (1)
  Sadia Butt (1)
  Samia Afzal (1)
  Irshad-ur Rehman (1)
  Ali Liaqat (1)
  Sana Saleem (1)
  Muhammad Ali (1)
  Azeem Butt (1)
  
  1. Molecular Virology Lab, National Centre of Excellence in Molecular Biology, University of the Punjab, 87-West Canal Bank Road Thokar Niaz Baig Lahore-53700, Lahore, Pakistan
  2. Department of Medicine, Lahore Medical and Dental College Lahore, Lahore, Pakistan
  
• ISSN：1743-422X

文摘

Background Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained virological response than standard IFN α/ribavirin therapy. Objective of current study was to analyze rate of early and delayed response to antiviral treatment as well as rate of relapse response in patients following standard treatment IFN α/ribavirin and in patients following pegylated interferon treatment. Methods Baseline serum samples of 153 patients enrolled for IFN α/ribavirin and 50 patients for PegIFN/ribavirin were collected. After total RNA extraction, genotyping was and HCV RNA viral load was done. Subsequently HCV RNA viral load was estimated at 4 weeks of treatment, at 12 weeks, at 24 or 48 weeks and finally after 6 months follow up period. All the data was statistically analyzed using fisher's exact test. Results Total 86 patients out of 153 patients following conventional IFN α/ribavirin therapy completed treatment and 69% of them showed Rapid Virological Response (RVR). Whereas 50 patients following PegIFN/ribavirin treatment completed treatment and 80% of them achieved RVR. Total 64 out of 86 patients following IFN α/ribavirin therapy completed follow up period and 53.5% of them achieved Sustainded Virologcal Response (SVR). Forty-five out of total 50 patients who received PegIFN/ribavirin treatment completed 6 months follow up period and among these 70% achieved SVR. SVR rates were significantly associated with RVR (p < 0.001), age (p < 0.001) and gender (p < 0.01) Conclusions Rate of sustained virological response can be determined by factors like rapid virological response and age since they share significant association with one another. More over rate of SVR was more prominent in males than in females.